A5084465090- Transplantation: Methods and Outcomes
- Heart Failure Treatment and Management
- Renal Transplantation Outcomes and Treatments
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Viral Infections and Immunology Research
- Cardiac pacing and defibrillation studies
- Cardiac Structural Anomalies and Repair
- Trypanosoma species research and implications
- Parathyroid Disorders and Treatments
- Mechanical Circulatory Support Devices
- Sarcoidosis and Beryllium Toxicity Research
- Pulmonary Hypertension Research and Treatments
- Eosinophilic Disorders and Syndromes
- Cardiomyopathy and Myosin Studies
- Cardiac Arrest and Resuscitation
- Organ Transplantation Techniques and Outcomes
- Synthesis and Biological Evaluation
- COVID-19 Clinical Research Studies
- Cardiovascular Function and Risk Factors
- Infective Endocarditis Diagnosis and Management
- Cardiac, Anesthesia and Surgical Outcomes
- Pneumocystis jirovecii pneumonia detection and treatment
- Neurological Complications and Syndromes
- Cytomegalovirus and herpesvirus research
- Bone and Joint Diseases
Hospital Israelita Albert Einstein
2009-2025
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
2012-2024
Universidade de São Paulo
2012-2024
Instituto do Coração
2013-2023
Methodist Hospital
2021
Prince Sultan University
2021
Sociedade Brasileira de Cardiologia
2021
Hospital do Coração
2017-2019
University of Oxford
2019
National Heart Institute
2019
Parte 1: Diretriz Brasileira de Insuficiencia Cardiaca Cronica […] e Aguda
1. Introdução Nos últimos anos, foram consolidados avanços expressivos no conhecimento de amiloidose cardíaca (AC), trazendo uma profunda reformulação do seu significado clínico. Além haver evidências convincentes que AC seja causa relativamente comum insuficiência com fração ejeção preservada (ICFEP), assistimos o surgimento terapias específicas modificadoras curso natural da doença, capazes prolongar a sobrevida dos pacientes acometidos. Em paralelo, relevantes progressos nas técnicas...
Introdução A última Diretriz de Insuficiência Cardíaca do Departamento da Sociedade Brasileira Cardiologia (DEIC/SBC) foi finalizada em março 2018. partir então, houve um importante número intervenções terapêuticas e abordagens diagnósticas que surgiram ou se consolidaram na prática clínica internacional pesquisa clínica. Ao lado disso, a pandemia COVID-19 trouxe-nos conhecimento sobre o modelo fisiopatológico agressão miocárdica muitas dúvidas acerca continuidade segurança dos medicamentos...
Background Sudden death has been considered the main cause of in patients with Chagas heart disease. Nevertheless, this information comes from a period before introduction drugs that changed natural history failure. We sought to study mode failure caused by disease, comparing non-Chagas cardiomyopathy. Methods and results examined REMADHE trial grouped according etiology (Chagas vs non-Chagas) death. The primary end-point was all-cause, sudden mortality; 342 were analyzed 185 (54.1%) died....
The identification of new biomarkers heart failure (HF) could help in its treatment. Previously, our group studied 89 patients with HF and showed that exhaled breath acetone (EBA) is a noninvasive biomarker diagnosis. However, there no data about the relevance EBA as prognosis.To evaluate whether give prognostic information reduced ejection fraction (HFrEF).After collection analysis by gas chromatography-mass spectrometry spectrophotometry, referred before were followed one year. Study...
The perioperative management of patients undergoing cardiac surgery is highly complex and involves numerous factors. There a strong association between complications. Brazilian Surgical Identification Study (BraSIS 2) aims to assess the incidence death early postoperative complications, identify potential risk factors, examine both demographic characteristics epidemiology cardiovascular procedures. BraSIS 2 multicenter observational study who undergo are admitted intensive care unit. primary...
National studies on decompensated heart failure (DHF) are key to the understanding of this condition in our midst.To determine characteristics DHF patients an emergency department.A total 212 diagnosed with who had been admitted department (EU) a cardiology hospital were prospectively evaluated. Clinical variables, form presentation and causes decompensation studied. In 100 patients, ancillary tests, prescription vasoactive drugs, length stay mortality also analyzed.There was predominance...
Exhaled breath acetone (EBA) has been described as a new biomarker of heart failure (HF) diagnosis. EBA concentration increases according to severity HF and is associated with poor prognosis, especially in acute decompensated HF. However, there are no data on chronic patients. The aim evaluate the role for predicting cardiac overall mortality In GENIUS-HF cohort, patients were enrolled between August 2012 December 2014. All had left ventricular ejection fraction ≤ 50%, diagnosis was...